ADC Therapeutics SA (ADCT) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NervGen Pharma (NGEN) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 44.1% versus a loss of 67.1%. Over five years, NGEN leads with a -7.9% price change compared with -94.4% for ADCT. ADC Therapeutics SA is the larger company by market cap ($203.0 million vs $188.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | NGEN |
|---|---|---|
| Share price | $1.59 | $1.75 |
| Market cap | $202.99M | $188.16M |
| 1-day change | +11.97% | +0.57% |
| YTD return | -59.77% | -68.93% |
| 1-year return | -67.05% | -44.12% |
| 5-year return | -94.42% | -7.94% |
| EPS (TTM) | $-0.60 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $6.30 |
| 52-week low | $0.78 | $1.58 |
| Distance from 52-week high | -68.07% | -72.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +109.43% | +471.43% |
| Average volume | 1.35M | 572.85K |
| Shares outstanding | 127.67M | 107.52M |
| Employees | 188 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGEN has outperformed ADCT by 22.9 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ADCT vs NGEN FAQ
Which is bigger, ADC Therapeutics SA or NervGen Pharma?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $202.99M compared with $188.16M for NervGen Pharma (NGEN).
Which stock has performed better over the past year, ADCT or NGEN?
NGEN returned -44.12% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and NervGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.